GlassScriptPhysician profile
John Nichols
NPI 1023108115
$3,810.17
in general payments reported to CMS, 2019-2025
24 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $119 · 2021: $393 · 2022: $524 · 2023: $1,172 · 2024: $607 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,370.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $795.53 | 2022-2023 | |
| Abbvie INC. | $333.20 | 2022-2025 | |
| Alcon Vision LLC | $318.36 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| Novartis Pharmaceuticals Corporation | $306.07 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $293.87 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $278.40 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $273.21 | 2023-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Dompe US, INC. | $229.64 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $226.84 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $143.02 | 2019-2023 | Tecnis Simplicity |
| Ocular Therapeutix, INC. | $135.58 | 2022-2025 | Dextenza |
| Glaukos Corporation | $88.97 | 2024 | Idose |
| Rayner Intraocular Lenses Limited | $82.40 | 2022-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Sight Sciences, INC. | $53.03 | 2022 | |
| Shire North American Group INC | $43.11 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $35.56 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $32.32 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $29.65 | 2024 | Triesence, Iheezo |
| Horizon Therapeutics Plc | $27.81 | 2019-2021 | |
| Biotissue Holdings INC. | $19.22 | 2021 | |
| Astellas Pharma US INC | $18.17 | 2025 | Izervay |
| Omeros Corporation | $16.67 | 2019 | |
| Aerie Pharmaceuticals, INC. | $16.45 | 2021 | |
| Allergan, INC. | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.